Effectiveness of an angiotensin II receptor blocker losartan as monoand combined therapy in hypertensive patients with various levels of renin-angiotensin-aldosterone system activity
Abstract
Aim. To study the role of angiotensin II receptor blockers (ARB), in particular, losartan, in mono- and combined therapy of patients with arterial hypertension (AH) and various renin-angiotensin profiles. To identify the patients with maximal effectiveness of antihypertensive treatment and maximal improvement in the levels of reninangiotensin-aldosterone system (RAAS) parameters.
Material and methods. The study included 399 patients, aged 18-65 years (mean age 53,4±7,6 years), with essential AH and mean levels of systolic and diastolic blood pressure (SDP, DBP) of 194,8±8,8 and 114,8±4,8 mm Hg, respectively. Plasma renin activity (PRA) and plasma aldosterone concentration (PAC) were measured by radioimmune methods.
Results. Losartan (50 mg/d) reduced DBP in patients with PRA 0,22-1,0 ng/ml/h and PAC/PRA 5-23 by 9,5% (р<0,05-0,01); in patients with PRA 1,0-3,0 ng/ml/h and normoaldosteronism – by 7,4% (p<0,05-0,01); in all the other subgroups – by 22,1-32% (p<0,01).
Conclusion. During ARB treatment, PAC reduction positively correlated with baseline PAC levels and negatively correlated with the magnitude of reactive PRA elevation. In patients with PRA <0,22 ng/ml/h, anti-aldosterone effect of ARB was attenuated. Losartan monotherapy (50 mg/d) normalised BP in all AH patients, with an exception of individuals with normoaldosteronism. The combination of losartan with nifedipine retard demonstrated wide therapeutic spectrum and good antihypertensive effect. The combination of losartan and atenolol was effective in all patients with increased sympatho-adrenal system activity
About the Authors
Sh. V. Akhadov
City Polyclinic No 81
Russian Federation
Moscow
Russian Federation
Moscow
G. R. Ruzbanova
City Polyclinic No 81
Russian Federation
Moscow
Russian Federation
Moscow
G. S. Molchanova
M.F. Vladimirsky Moscow Region Institute of Clinical Research
Russian Federation
Moscow
Russian Federation
Moscow
S. N. Khoreva
M.F. Vladimirsky Moscow Region Institute of Clinical Research
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonist: A new approaches to blockade of the renin-angiotensin system. Am Heart J 1994; 127: 1388-401.
2. Bauer JH, Reams GP. The angiotensin II type I receptor antagonists: a new class of antihypertensive drugs. Arch Intern Med 1995; 155: 1361-8.
3. Сидоренко Б.А., Иосава И.К., Киктев В.Г., Преображенский Д.В. Блокаторы АТ1-ангиотензиновых рецепторов как новая группа антигипертензивных препаратов. Клин. фармакол. 1999; 6: 64-9.
4. Willenheimer R, Dahlof B, Rydberg E, Erhardt L. AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions. Eur Heart J 1999; 20 (14): 997-1008.
5. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. Br Med J 2004; 329: 1248-9.
6. Volpe M, Mancia G, Trimarco B. Angiotensin receptor blockers and myocardial infarction: the importance of dosage. J Hypertens 2006; 24: 1681-2.
7. Verdecchia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J 2005; 26: 2381-6.
8. Blood Pressure Lowering Treatment Trialists Collaboration. Blood pressure dependent and effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 23: 951-8.
9. The Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiolody. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-87.
10. Jounela AJ, Lilja M, Lumme J. Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects. Blood Press 1994; 3(4): 231-5.
11. Kjeldsen SE, Dahlof B, Devereux RB, et al. for the Losartan Intervention for Endpoint reduction (LIFE) study group. Benefits of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hyperthrophy: a LIFE substudy. JAMA 2002; 288: 1491-8.
12. Dahlof B, Devereux RB, Kjeldsen SE, et al. for the Losartan Intervention for Endpoint reduction (LIFE) study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
13. Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study) J Hypertens 2003; 21: 1563-74.
14. Hasebe N, Kikuch K. Controlled Release Nifedipine and Candesartan Low-Dose Combination Therapy in Patients with Essential Hypertension: NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 2005; 23: 445-53.
15. Bakris G, Molitch M, Hewkin A, et al. STAR Investigators Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592-7.
16. Sasaki H, Kanai S, Oyama T, et al. Effect of combination therapy of benidipine hydrochloride and candesartan cilexetil on serum lipid metabolism and blood pressure in elderly hypertensive patients with type 2 diabetes mellitus. J Atheroscler Thromb 2006; 13(3): 149-57.
Review
For citations:
Akhadov Sh.V., Ruzbanova G.R., Molchanova G.S., Khoreva S.N. Effectiveness of an angiotensin II receptor blocker losartan as monoand combined therapy in hypertensive patients with various levels of renin-angiotensin-aldosterone system activity. Cardiovascular Therapy and Prevention. 2011;10(1):30-37. (In Russ.)
Views:
820
Email this article 
